María
Díez Campelo
University of Florence
Florencia, ItaliaUniversity of Florence-ko ikertzaileekin lankidetzan egindako argitalpenak (9)
2024
-
CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)
Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25
-
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 403, Núm. 10423, pp. 249-260
2022
2021
-
Imetelstat achieves meaningful and durable transfusion independence in high transfusion–Burden patients with lower-risk myelodysplastic syndromes in a phase II study
Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 48-56
-
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 13, pp. 1426-1436
2020
2017
-
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
Journal of Clinical Oncology, Vol. 35, Núm. 14, pp. 1591-1597